Eye disease biotech Avalanche Biotechnologies sets terms for $76 million IPO


Shutterstock photo

Avalanche Biotechnologies, a early-stage biotech developing gene therapies for wet AMD and other ophthalmic diseases, announced terms for its IPO on Monday. The Menlo Park, CA-based company plans to raise $76 million by offering 5.4 million shares at a price range of $13 to $15. At the midpoint of the proposed range. Avalanche would command a fully diluted market value of $353 million.

Avalanche Biotechnologies, which was founded in 2006, plans to list on the NASDAQ under the symbol AAVL. Jefferies & Co., Cowen & Company, Piper Jaffray are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com